This site is intended for health professionals only

Home / News / Common cardiovascular and diabetes drugs potentially effective in tackling mental health issues, study finds

Common cardiovascular and diabetes drugs potentially effective in tackling mental health issues, study finds

Girl holding her head

By Léa Legraien
Reporter

11 Jan 2019

Commonly prescribed drugs for diabetes, heart conditions and high blood pressure could help treat severe mental health problems, a study has shown.

Researchers at the University College London (UCL), the Karolinska Institute, Sweden and the University of Hong Kong found that the use of hydroxylmethyl glutaryl coenzyme A reductase inhibitors (HMG-CoA RIs), L-type calcium channel antagonists (LTCC) and biguanides on mentally ill patients reduced the number of their psychiatric hospitalisation admissions and self harm.

The study, published on 9 January in the medical journal JAMA Psychiatry, analysed the health records of 142,691 Swedish patients with bipolar disorder, schizophrenia and non-affective psychosis between April and August 2018.

 

Fewer hospitalisation rates

 

The study showed that patients taking HMG-CoA RIs, LTCC and biguanides such as metformin were less likely to be admitted to a psychiatric hospital than when they were off the medicines.

The findings also highlighted a reduction in self harm in patients with bipolar disorder and schizophrenia subject to the drugs and in patients with non-affective psychosis taking LTCC.

 

Common drugs

 

The study’s lead author Dr Joseph Hayes said that HMG-CoA RIs, LTCC and biguanides are ‘ideal to treat severe mental health problems’ as they are ‘globally licensed, commonly used, cheap and relatively safe medications’.

He added: ‘Serious mental illnesses, including bipolar disorder, are associated with high levels of morbidity and are challenging to treat.

‘Many widely used drugs, such as statins, have long been identified as having the potential for repurposing to benefit these disorders.

‘Our research provides additional evidence that exposure to HMG-CoA RIs, LTCC antagonists and biguanides might lead to improved outcomes for individuals with serious mental illnesses.’


Want news like this straight to your inbox?


Latest News

Government appoints Maggie Throup as new pharmacy minister
Maggie Throup has been appointed as the new parliamentary under-secretary of state for prevention, public...
Covid symptoms
Failure to update Covid symptom list ‘is killing people’, leading researcher warns
The Government’s out-of-date advice on Covid symptoms that should trigger a PCR test could be...
pharmacies booster vaccine
LloydsPharmacy and Boots confirm branches will deliver booster vaccines
An additional 11 of LloydsPharmacy’s 1,400 stores in the UK have been commissioned to deliver the Covid booster jab, the...